Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06703632

Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
4,538 (estimated)
Sponsor
ADVANCED MARKER DISCOVERY S.L. · Industry
Sex
All
Age
50 Years – 69 Years
Healthy volunteers
Accepted

Summary

The objective of this low-risk interventional study is to evaluate whether the PreveCol® test has sufficient efficiency to be considered as a second-line method for the detection of both colorectal cancer and advanced adenomas when used prospectively in the screening population with a previous positive FOBT result, which could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to be answered are: * Values of efficacy, efficiency, impact and safety of PreveCol. * Values of preferences of participants for screening methods. * Values of PREMs into screening programme. Participants will provide a blood sample prior to a screening colonoscopy, and complete two questionnaires. They will give their sample, information and clinical data to the investigator or health care personnel.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTblood samplingPreveCol test based on blood sampling
OTHERSurvey using a questionnaire.Preference questionnaire for colorectal cancer screening methods
OTHERSurvey using a questionnaire.PREMs for colorectal cancer screening programme

Timeline

Start date
2025-01-14
Primary completion
2025-11-01
Completion
2025-12-01
First posted
2024-11-25
Last updated
2025-02-27

Locations

2 sites across 2 countries: Portugal, Spain

Source: ClinicalTrials.gov record NCT06703632. Inclusion in this directory is not an endorsement.